PAI
ACAD icon

Palo Alto Investors’s Acadia Pharmaceuticals ACAD Stock Holding History

Palo Alto Investors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63.9M Buy
2,872,695
+388,664
+16% +$9.29M 9.78% 2
2025
Q4 		$66.3M Buy
2,484,031
+17,347
+0.7% +$415K 9.24% 4
2025
Q3 		$52.6M Sell
2,466,684
-96,525
-4% -$2.28M 9.74% 3
2025
Q2 		$55.3M Sell
2,563,209
-100,716
-4% -$1.87M 11.76% 2
2025
Q1 		$44.2M Sell
2,663,925
-84,674
-3% -$1.54M 8.43% 4
2024
Q4 		$50.4M Buy
2,748,599
+224,643
+9% +$3.63M 7.82% 5
2024
Q3 		$38.8M Buy
2,523,956
+105,115
+4% +$1.75M 5.04% 7
2024
Q2 		$39.3M Buy
2,418,841
+3,898
+0.2% +$62.9K 4.55% 8
2024
Q1 		$44.7M Buy
2,414,943
+5,387
+0.2% +$133K 5.04% 7
2023
Q4 		$75.4M Buy
2,409,556
+3,763
+0.2% +$89.9K 6.8% 6
2023
Q3 		$50.1M Hold
2,405,793
– – 4.74% 9
2023
Q2 		$57.6M Hold
2,405,793
– – 4.65% 9
2023
Q1 		$45.3M Buy
2,405,793
+29,424
+1% +$560K 3.75% 9
2022
Q4 		$37.8M Buy
2,376,369
+698,173
+42% +$10.9M 3.23% 9
2022
Q3 		$27.5M Hold
1,678,196
– – 2.17% 12
2022
Q2 		$23.6M Sell
1,678,196
-573,638
-25% -$10.7M 2.06% 13
2022
Q1 		$54.5M Sell
2,251,834
-86,043
-4% -$2.08M 4.22% 10
2021
Q4 		$54.6M Hold
2,337,877
– – 3.49% 10
2021
Q3 		$38.8M Hold
2,337,877
– – 2.34% 12
2021
Q2 		$57M Hold
2,337,877
– – 3.14% 12
2021
Q1 		$60.3M Buy
2,337,877
+36,400
+2% +$1.6M 3.44% 10
2020
Q4 		$123M Buy
2,301,477
+469,177
+26% +$23.3M 6.45% 6
2020
Q3 		$75.6M Buy
1,832,300
+267,400
+17% +$11.5M 4.15% 9
2020
Q2 		$75.9M Sell
1,564,900
-66,624
-4% -$3.2M 4.55% 10
2020
Q1 		$68.9M Sell
1,631,524
-273,850
-14% -$11.3M 5.77% 9
2019
Q4 		$81.5M Sell
1,905,374
-271,303
-12% -$11.8M 4.49% 11
2019
Q3 		$78.3M Sell
2,176,677
-132,126
-6% -$4.01M 5.22% 9
2019
Q2 		$61.7M Buy
2,308,803
+60,400
+3% +$1.54M 3% 15
2019
Q1 		$60.4M Buy
2,248,403
+222,340
+11% +$5.19M 2.52% 15
2018
Q4 		$32.8M Buy
2,026,063
+341,883
+20% +$6.64M 1.74% 19
2018
Q3 		$35M Buy
1,684,180
+33,400
+2% +$525K 1.41% 20
2018
Q2 		$25.2M Hold
1,650,780
– – 1.01% 22
2018
Q1 		$37.1M Buy
1,650,780
+9,750
+0.6% +$270K 1.59% 19
2017
Q4 		$49.4M Hold
1,641,030
– – 2.13% 14
2017
Q3 		$61.8M Buy
1,641,030
+27,700
+2% +$901K 2.6% 13
2017
Q2 		$45M Buy
1,613,330
+22,900
+1% +$682K 2.1% 14
2017
Q1 		$54.7M Buy
1,590,430
+58,400
+4% +$2.06M 2.58% 15
2016
Q4 		$44.2M Buy
1,532,030
+50,100
+3% +$1.33M 2.52% 13
2016
Q3 		$47.1M Buy
1,481,930
+44,200
+3% +$1.5M 2.74% 13
2016
Q2 		$46.7M Buy
1,437,730
+952,630
+196% +$31.9M 3.53% 8
2016
Q1 		$13.6M Buy
+485,100
New +$10.6M 1.05% 25

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Palo Alto Investors's ACAD Position: Q1 2026 in Review

Palo Alto Investors increased its Acadia Pharmaceuticals (ACAD) stake by 16% in Q1 2026, buying an estimated $9.29M and bringing the position to 2,872,695 shares worth $63.9M. The position accounts for 9.78% of the portfolio, ranked #2.

Palo Alto Investors first reported a position in ACAD in Q1 2016 and has held it in 41 quarters since. The position peaked at $123M in Q4 2020. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Palo Alto Investors held 2,872,695 shares of Acadia Pharmaceuticals worth $63.9M as of Q1 2026.
  • Palo Alto Investors bought 388,664 Acadia Pharmaceuticals shares in Q1 2026, an estimated $9.29M.
  • Acadia Pharmaceuticals made up 9.78% of Palo Alto Investors's portfolio in Q1 2026, its #2 holding.
  • Palo Alto Investors first reported a position in Acadia Pharmaceuticals in Q1 2016 and has held it in 41 quarters since.
  • Palo Alto Investors's Acadia Pharmaceuticals position peaked at $123M in Q4 2020.
  • 341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.